EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy

Benedetto Ferraresi iD, Antonio Nenna iD, Mohamad Jawabra, Diletta Corrado iD, Andrea Faggiano, Stefano Carugo, Carmelo Dominici, Giovanni Casali, Massimo Chello, Mario Lusini iD

Journal of Cardiovascular Development and Disease · 29.04.2026 · 13 (5) · 187

DOI: 10.3390/jcdd13050187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 29.04.2026. Verfasst von Benedetto Ferraresi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hypercontractility, offering significant reductions in left ventricular outflow tract (LVOT) gradients and improved functional capacity. This review evaluates the evolving role of CMIs in refining surgical candidate selection and postoperative care. Clinically, CMIs function as an in vivo “biological test” to distinguish between dynamic, functional obstruction—often manageable with medication—and fixed anatomical obstruction driven by complex septal or mitral substrates. While clinical trials demonstrate that CMIs can delay or prevent the need for SRT in a significant proportion of patients, surgery remains the definitive solution for those with dominant structural anomalies or drug intolerance. Consequently, the therapeutic paradigm is shifting from a binary “drugs or surgery” approach to a synergistic model. In this framework, CMIs optimize the identification of patients truly requiring structural myectomy while serving as a valuable adjunct for managing residual hypercontractility, ultimately facilitating a personalized, multidisciplinary approach to HCM treatment.

Schlagwörter

Stichwörter der Autor:innen

cardiac myosin inhibitorshypertrophic cardiomyopathymavacamtenseptal reduction therapysurgical myectomy

Autor:innen und Institutionen

  • Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy.
  • Unit of Cardiac Surgery, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Department of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Milan, Italy.
  • Cardiac Surgery, Azienda Ospedaliero Universitaria Maggiore Della Carità di Novara, Corso Mazzini 18, 28100 Novara, Italy.

ORCID-Profile: Benedetto Ferraresi, Antonio Nenna, Diletta Corrado, Mario Lusini

Zitieren

APA

Ferraresi, B., Nenna, A., Jawabra, M., Corrado, D., Faggiano, A., Carugo, S., Dominici, C., Casali, G., Chello, M., & Lusini, M. (2026). Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Development and Disease, 13(5), 187. https://doi.org/10.3390/jcdd13050187

Vancouver

Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, et al. Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Development and Disease. 2026;13(5):187. doi:10.3390/jcdd13050187

BibTeX
@article{Ferraresi2026,
  author = {Ferraresi, Benedetto and Nenna, Antonio and Jawabra, Mohamad and Corrado, Diletta and Faggiano, Andrea and Carugo, Stefano and Dominici, Carmelo and Casali, Giovanni and Chello, Massimo and Lusini, Mario},
  title = {Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2026},
  volume = {13},
  number = {5},
  pages = {187},
  doi = {10.3390/jcdd13050187}
}
Kostenlos starten →